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Abstract
Background: Post-arthroplasty infections represent a devastating complication of total joint replacement surgery, resulting
in multiple reoperations, prolonged antibiotic use, extended disability and worse clinical outcomes. As the number of
arthroplasties in the U.S. will exceed 3.8 million surgeries per year by 2030, the number of post-arthroplasty infections is
projected to increase to over 266,000 infections annually. The treatment of these infections will exhaust healthcare
resources and dramatically increase medical costs.
Methodology/Principal Findings: To evaluate novel preventative therapeutic strategies against post-arthroplasty
infections, a mouse model was developed in which a bioluminescent Staphylococcus aureus strain was inoculated into a
knee joint containing an orthopaedic implant and advanced in vivo imaging was used to measure the bacterial burden in
real-time. Mice inoculated with 56103 and 56104 CFUs developed increased bacterial counts with marked swelling of the
affected leg, consistent with an acute joint infection. In contrast, mice inoculated with 56102 CFUs developed a low-grade
infection, resembling a more chronic infection. Ex vivo bacterial counts highly correlated with in vivo bioluminescence
signals and EGFP-neutrophil fluorescence of LysEGFP mice was used to measure the infection-induced inflammation.
Furthermore, biofilm formation on the implants was visualized at 7 and 14 postoperative days by variable-pressure scanning
electron microscopy (VP-SEM). Using this model, a minocycline/rifampin-impregnated bioresorbable polymer implant
coating was effective in reducing the infection, decreasing inflammation and preventing biofilm formation.
Conclusions/Significance: Taken together, this mouse model may represent an alternative pre-clinical screening tool to
evaluate novel in vivo therapeutic strategies before studies in larger animals and in human subjects. Furthermore, the
antibiotic-polymer implant coating evaluated in this study was clinically effective, suggesting the potential for this strategy
as a therapeutic intervention to combat post-arthroplasty infections.
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Introduction
The incidence of infections after total joint replacement surgery
has increased over the past decade despite the widespread use of
intravenous antibiotic prophylaxis and a focus on aseptic surgical
technique [1,2]. Post-arthroplasty infections still occur in ,1.2% of
primary arthroplasties and 3–5% of revisions [1,3–5]. As the
demand for joint replacements increases with the aging population,
the total number of infections is projected to rise from 17,000 to
266,000 per year by 2030 as the number of arthroplasties exceeds 3.8
million surgeries [1,2,6,7]. The treatment of a post-arthroplasty
infection is exceedingly difficult. Bacteria (especially S. aureus) form
extracellular anionic polysaccharide biofilms on implanted metallic/
plastic materials that block penetration of immune cells and
antibiotics, promoting bacterial survival [8–11]. Once a biofilm is
formed, surgical removal of all the implanted materials is necessary
[8–11]. Most of these infections are caused by staphylococcal species
(,70%) [12–14] and an increasing number are due to virulent
antibiotic-resistant strains such as methicillin-resistant S. aureus
(MRSA) [15], which further complicate treatment [12–14].
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The current standard of care in the U.S. to treat a chronic
post-arthroplasty infection is a two-stage procedure beginning
with (1) surgical removal of all prosthetic components and bone
cement, debridement of necrotic/granulation tissue, placement
of an antibiotic-impregnated spacer, administration of a 6-week
course of intravenous antibiotics (during which the patient is
unable to bear weight on the affected limb), and (2) revision
arthroplasty after the infection has cleared [16–21]. In severe
infections and refractory cases, arthrodesis, resection arthroplas-
ty and amputation are sometimes necessary [22–24]. In the
elderly, these infections result in increased mortality [25,26].
Overall, the treatment of post-arthroplasty infection involves
extensive medical and surgical care, prolonged disability/
rehabilitation and significantly worse outcomes [1,2,7]. In
addition, these infections represent an enormous economic
burden due to additional medical costs and resource utilization
as well as indirectly through lost wages and productivity [1,2,6].
These medical costs alone average $144,514 (compared with
$30,173 for an uncomplicated arthroplasty) [2], which corre-
spond to an annual national healthcare burden of $8.63 billion
by 2015 [7].
Most post-arthroplasty infections are thought to be caused by
invading bacteria at the time of surgery [27–29]. As treatment of
infected implanted materials is exceedingly difficult, especially
due to the inherent difficulties in treating an established biofilm
[30,31], one potential therapeutic strategy is to focus on the
prevention of infection [27–29]. Previous animal models used to
study post-arthroplasty joint infection have been performed in
dogs [32–34], rabbits [35–41] and rats [42,43]. These studies
suggested that local antibiotic therapy in the joint at the time of
surgery, including direct antibiotic or antimicrobial agents that
are coated or covalently-linked directly to the prosthetic
materials, can decrease post-arthroplasty infections by preventing
bacterial seeding of the implants at the time of surgery [32–43].
Although these studies using larger animals provide extremely
useful preclinical information, these studies are costly, labor
intensive and require significant animal usage as euthanasia is
required to determine the bacteria burden. The major goal of this
study was to develop a mouse model of post-arthroplasty
Staphylococcus aureus infection that would combine the use of
bioluminescent bacteria and genetically engineered mice that
possess fluorescent neutrophils (LysEGFP mice) with advanced
techniques of in vivo whole animal imaging to noninvasively
measure infection and inflammation in real-time, without
requiring euthanasia. It is our hope that this model could be
used as a rapid, accurate and inexpensive in vivo preclinical
screening tool to evaluate the in vivo efficacy of potential strategies
to prevent or treat post-arthroplasty infections. Therapeutic
strategies that were successful in this mouse model could be
confirmed in more extensive large animal or human studies,
preventing the need to perform these expensive and time
consuming studies on all candidate therapies.
Materials And Methods
Ethics statement
All animals were handled in strict accordance with good animal
practice as defined in the federal regulations as set forth in the
Animal Welfare Act (AWA), the 1996 Guide for the Care and Use
of Laboratory Animals, PHS Policy for the Humane Care and Use
of Laboratory Animals, as well as UCLA’s policies and procedures
as set forth in the UCLA Animal Care and Use Training Manual,
and all animal work was approved by the UCLA Chancellor’s
Animal Research Committee (ARC#: 2008-112).
S. aureus bioluminescent strain
The bioluminescent S. aureus SH1000 strain, ALC2906, which
contains the shuttle plasmid pSK236 with the penicillin-binding
protein 2 (pbp2) promoter fused to the luxABCDE reporter cassette
from Photorhabdus luminescens, was used in all experiments [44–46].
This S. aureus strain naturally emits bioluminescent signals from
live, actively metabolizing bacteria in all stages of the S. aureus life
cycle [44–46].
Preparation of S. aureus for inoculation into the joint
space
S. aureus bioluminescent strain ALC2906 has a chloramphenicol
resistance selection marker and chloramphenicol (10 mg/ml;
Sigma-Aldrich) was supplemented to all cultures. S. aureus was
streaked onto tryptic soy agar plates (tryptic soy broth [TSB] plus
1.5% bacto agar [BD Biosciences]) and grown at 37uC overnight
[44–46]. Single colonies of S. aureus were cultured in TSB and
grown overnight at 37uC in a shaking incubator (240 rpm) (MaxQ
4450; Thermo) [44–46]. Mid-logarithmic phase bacteria were
obtained after a 2 h subculture of a 1/50 dilution of the overnight
culture [44–46]. Bacterial cells were pelleted, resuspended and
washed 3x in PBS. Bacterial concentrations were estimated by
measuring the absorbance at 600 nm (A600; Biomate 3 [Thermo]).
Colony forming units (CFUs) were verified after overnight culture
of plates [44–46].
Mice
12-week old male C57BL/6 wildtype mice were used (Jackson
Laboratories). In some experiments, 12-week old male LysEGFP
mice, a genetically engineered mouse line on a C57BL/6
background possessing green-fluorescent myeloid cells (mostly
neutrophils) as a consequence of ‘knockin’ of enhanced green
fluorescence protein (EGFP) into the lysozyme M gene, were used
[47,48].
Mouse surgical procedures
Mice were anesthetized via inhalation isoflurane (2%). The
surgical procedure was modified from previous work [49,50]. A
skin incision was made over the right knee (Figure 1A). The distal
right femur was accessed through a medial parapatellar arthrot-
omy with lateral displacement of the quadriceps-patellar complex
(Figure 1B). After locating the femoral intercondylar notch
(Figure 1B), the femoral intramedullary canal was manually
reamed with a 25 gauge needle (Figure 1C). An orthopaedic-grade
stainless steel Kirschner (K)-wire (diameter 0.6 mm) (Synthes) was
surgically placed in a retrograde fashion and cut with 1 mm
protruding into the joint space (Figure 1D). An inoculum of S.
aureus in 2 ml of normal saline was pipetted into the joint space
containing the cut end of the implant (Figure 1E). The quadriceps-
patellar complex was reduced to the midline (Figure 1F) and the
surgical site was closed with Dexon 5-0 sutures (Figure 1G). A
representative radiograph demonstrates the position of the implant
with good intramedually fixation of the stem and prominence of
the cut surface in the joint (Figure 1H). Buprenorphine (0.1 mg/
kg) was administered subcutaneously every 12 hours as an
analgesic for the duration of the experiment.
Quantification of in vivo S. aureus (in vivo
bioluminescence imaging and colony forming units
[CFUs])
Mice were anesthetized via inhalation of isoflurane (2%) and in
vivo bioluminescence imaging was performed by using the
Xenogen in vivo imaging system (Xenogen IVISH; Caliper Life
Post-Arthroplasty Infection
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Sciences) [44–46]. Data are presented on color scale overlaid on a
grayscale photograph of mice and quantified as maximum flux
(photons per second (s) per cm2 per steradian (sr) [p/s/cm2/sr])
within a circular region of interest (16103 pixels) by using Living
ImageH software (Xenogen). To confirm that the bioluminescence
signals corresponded to the bacterial burden in vivo, bacteria
adherent to the implants were quantified by detaching the bacteria
from the implant by sonication in 1 ml 0.3% Tween-80 in TSB for
10 minutes followed by vortexing for 5 minutes as previously
described [51]. In addition, bacteria in the joint tissue were
confirmed by homogenizing bone and joint tissue (Pro200H Series
homogenizer; Pro Scientific). The number of bacterial CFUs that
were adherent to the implant and in the joint tissue was
determined by counting CFUs after overnight culture of plates
and was expressed as total CFUs harvested from the implant and
joint tissue.
Quantification of neutrophil recruitment to the infected
post-operative joint (in vivo fluorescence imaging)
To obtain a measurement of neutrophil infiltration, LysEGFP
mice were used. After in vivo bioluminescence imaging, in vivo
fluorescence imaging was performed by using the Xenogen
IVISH (Caliper Life Sciences). EGFP-expressing neutrophils
within the post-operative site were visualized by using the GFP
filter for excitation (445–490 nm) and emission (515–575 nm) at
an exposure time of 0.5 seconds [47,48]. Data are presented on
color scale overlaid on a grayscale photograph of mice and
quantified as total flux (photons/s) within a circular region of
interest (16103 pixels) by using Living ImageH software
(Xenogen).
Histologic analysis
Mice were euthanized via inhalation carbon dioxide and joint
specimens were fixed in formalin (10%) overnight. Specimens were
decalcified by incubation in Decalcifier IIH solution (Surgipath) for
6 h and specimens were processed and embedded in paraffin.
Sagittal sections of 4 mm thickness were cut and then were stained
with hematoxylin and eosin (H&E) and Gram stain.
Variable-pressure scanning electron microscopy
A field emission variable pressure scanning electron microscope
(FE-SEM Zeiss Supra VP40) was used to obtain a digital image of
the cut end of the implants. Conductive graphite glue was used to
position the pins on a graphite stub. Pressure in the microscope
chamber was maintained at 25Pa, which allowed the examination
of the implant surface without the need of sputter coating.
Secondary and in-lens detectors were used to reveal the
topographical characteristics of the surface. Examination of the
implant occurred at regular intervals by tilting the pin between24
and 10 degrees and rotating it every 30 degrees for a total of 360
degrees.
Coating of metallic implants with an antibiotic-
impregnated bioresorbable polymer
A bioresorbable polymer impregnated with rifampin and
minocycline, which was modified from FDA-approved mesh
coatings to prevent infection of pacemakers and implantable
cardioverter defibrillators (PivitTM AB and AigisRxTM CRM;
TyRx Pharma, Inc.), was used (50). To coat the stainless steel K-
wire implants with this antibiotic-impregnated polymer, K-wires
were hand-dipped in a mixture of a bioresorbable tyrosine-derived
Figure 1. Mouse surgical procedures. (A) An incision was made in the skin overlying the right knee joint (arrow). (B) A medial parapatellar
arthrotomy with lateral displacement of the quadriceps-patellar complex was performed to locate the intercondylar femoral notch (arrow). (C) An
intramedullary canal was manually reamed into the distal femur with a 25 gauge needle. (D) An orthopaedic-grade stainless steel K-wire (diameter
0.6 mm) was surgically placed in a retrograde fashion into the intramedullary canal and cut so that the cut end extended 1 mm into the joint space.
(E) An inoculum of S. aureus in a 2 ml volume was pipetted into the joint space (arrow). (F) The quadriceps-patellar complex was reduced back to the
midline (arrow) and (G) the surgical site was closed with subcutaneous 5-0 Dexon sutures (arrow). (H) A representative radiographic image
demonstrating the placement of the implant in the femoral canal with the cut end extending into the knee joint.
doi:10.1371/journal.pone.0012580.g001
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polyesteramide rifampin and minocycline and methylene chloride.
Vehicle coating consisted of bioresorbable tyrosine-derived poly-
esteramide and methylene chloride only (no antibiotic). The
coated pins were heat dried for at least 12 h until residual solvent
was less than 600 ppm, stored at 215uC and sterilized by gamma
irradiation. Three different formulations were generated (Coatings
A, B and C) with the following approximate antibiotic concentra-
tions: Coating A: 32.5 mg/mm3 of rifampin and 36.1 mg/mm3 of
minocycline; Coating B: 46.1 mg/mm3 of rifampin and 47.7 mg/
mm3 of minocycline; and Coating C: 97.4 mg/mm3 of rifampin
and 104.2 mg/mm3 of minocycline. The coatings were repeatedly
dipped until the thickness of Coating A and Coating B were ,40–
45 mm whereas and Coating C was ,80–90 mm. Thus, Coatings
A and B would elute at the same rate whereas Coating C would
elute slower because it had double the coating thickness.
Statistical analysis
Data were compared by using a Student’s t-test (two-tailed). All
data are expressed as mean 6 standard error of the mean (sem)
where indicated. Values of p,0.05, p,0.01 and p,0.001 were
considered statistically significant.
Results
In vivo bioluminescence imaging to measure the
bacterial burden in real-time
To model a post-arthroplasty infection, an orthopaedic-grade
K-wire (Synthes, Inc., West Chester, PA) was surgically placed into
the femur with the cut end protruding into knee joint and an
inoculum of S. aureus was pipetted into the joint space before
closure (Figure 1). To measure the bacterial burden within the
infected post-operative joints in real-time, we used a biolumines-
cent S. aureus strain (SH1000) that naturally emits lights from
live, ATP-producing bacteria at all stages of the S. aureus life cycle
[44–46]. The bacterial burden was subsequently measured on
post-operative days 0, 1, 3, 5, 7 and 10 in anesthetized mice in
real-time by using the Xenogen in vivo imaging system (Xenogen
IVISH; Caliper Life Sciences) [44–46].
To determine the optimal bacterial inoculum to produce a
chronic implant infection, C57BL/6 mice were inoculated with
increasing logarithmic concentrations of S. aureus (56102, 56103
and 56104 CFUs/2 ml). During the first 5 days after the
inoculation, mice that received 56103 or 56104 CFUs had 20-
to 50-fold higher bioluminescence signals than uninfected mice
(Figure 2A, B). Clinically, both of these groups of mice developed
marked inflammation as characterized by increased swelling and
decreased mobility of the affected leg and were euthanized on
post-operative day 5. Thus, inocula of 56103 or 56104 CFUs of S.
aureus induced markedly high bioluminescent signals and produced
clinical signs of infection that was consistent with an acute purulent
joint infection. In contrast, mice that received an inoculum of
56102 CFUs developed signs of infection in the affected leg that
were only minimally different than uninfected mice. These mice
had up to 6- to 8-fold higher bioluminescence signals than the
background levels of uninfected control mice at all post-operative
days through day 10 (Figure 2A, B). The mild clinical findings
combined with the low level of bacterial bioluminescence allowed
us to follow the infection in the mice that received the inoculum
of 56102 CFUs for at least 10 days, which more closely resem-
bled a chronic and persistent infection. Thus, the inoculum of
56102 CFUs was used in all subsequent experiments.
To confirm that the in vivo bioluminescence signals accurately
represented the bacterial burden in vivo, traditional bacterial counts
were performed on post-operative day 5 from bacteria adherent to
the implant and present in the joint tissue (Figure 2C). Mice that
were inoculated with 56104, 56103 and 56102 CFUs had a total
bacterial burden ex vivo of 8.36105, 16105 and 2.46104 CFUs,
respectively (Figure 2C). In addition, the in vivo bioluminescent
signals correlated with the corresponding ex vivo bacterial CFUs
(correlation coefficient of determination: R2= 0.9873; Figure 2D),
suggesting that the in vivo bioluminescence signals at least through
day 5 provided an approximation of the actual bacterial burden in
vivo. However, since the bacterial strain used had the lux genes in a
plasmid that is maintained in vitro under chloramphenicol
selection, the plasmid is likely lost during the in vivo infection over
time. In broth culture without selection, the plasmid was stable for
the first 3 days in vitro with greater than 97% of bacteria still
containing the plasmid whereas only 53%, 38% and 21% of the
bacteria still contained the plasmid on days 5, 7 and 10,
respectively (data not shown). Thus, although the bioluminescent
signals obtained with this strain provide an approximation of the
bacterial burden in vivo, it is likely an underestimate of the actual
bacterial burden, especially at later time points.
In vivo fluorescence imaging to measure neutrophil
infiltration in real-time
The degree of inflammation within the post-operative knee joints
was measured by quantifying neutrophil infiltration, a key correlate
for inflammation and infection. This was accomplished by using in
vivo fluorescence imaging of LysEGFP mice, a genetically
engineered mouse strain that possesses green-fluorescent neutro-
phils [47,48]. The bioluminescent S. aureus strain infected into the
knee joints of LysEGFP mice enabled simultaneous measurement of
both bacterial burden and neutrophil infiltration on post-operative
days 0, 1, 3, 5, 7 and 10 (Figure 3). Similar to C57BL/6 mice in
Figure 2, S. aureus (56102 CFUs)-infected LysEGFP mice developed
bioluminescence signals that were up to 8-fold higher than the
background levels of uninfected control mice through day 10
(Figure 3A). In addition, the S. aureus-infected LysEGFP mice had
20–40% higher EGFP-neutrophil fluorescent signals than uninfect-
ed control mice on all post-operative days 1 to 10 (Figure 3B). This
degree of neutrophil recruitment, confirms our clinical observations
that the inoculum of 56102 CFUs produced a low-grade
inflammatory response, suggesting that EGFP-neutrophil fluores-
cence provides a quantifiable measurement of the clinical
inflammation observed in our model.
Histologic analysis of post-operative knee joints
To determine the location of the inflammatory infiltrate and
bacterial inoculum within the infected post-operative joints,
histologic sections were harvested from S. aureus-inoculated
(56102 CFUs) and uninfected control mice on post-operative
day 1 (Figure 4). Mice inoculated with S. aureus had increased
neutrophils in the joint tissue as seen in hematoxylin & eosin
(H&E) stained sections. In addition, Gram-positive (blue-staining)
bacteria could be readily detected in areas of inflammatory cells.
In contrast, uninfected control mice that only had the surgical
implant placed had minimal neutrophil infiltration and no bacteria
were detected by Gram-stain. These histologic findings corrobo-
rate our in vivo bioluminescence and fluorescence imaging data
demonstrating that the inoculum of 56102 CFUs of S. aureus
induced neutrophil infiltration and bacterial proliferation in the
joint tissue in the area of the implant.
Detection of biofilm formation on the metallic implants
To evaluate whether biofilm formation occurred on the
implants in our mouse model, implants were harvested from
Post-Arthroplasty Infection
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Figure 2. Measurement of bacterial burden using in vivo bioluminescence. After surgical placement of an orthopaedic-grade stainless steel
K-wire into the distal femur, 56104, 56103 and 56102 CFUs/2 ml of S. aureus or 2 ml of saline alone (uninfected) were inoculated into the knee joint
tissue in the area of the cut end of the implant (n = 7 mice per group). (A) Bacterial counts as measured by in vivo S. aureus bioluminescence (mean
maximum flux [p/s/cm2/sr] 6 sem) (logarithmic scale). (B) Representative in vivo S. aureus bioluminescence on a color scale overlaid on top of a
grayscale image of mice. (C) Bacteria adherent to the implants and present in the joint tissue were harvested from mice on post-operative day 5 and
CFUs were determined after overnight culture. (D) Correlation between in vivo bioluminescence signals and total CFUs harvested from the infected
implants and joint tissue on post-operative day 5. The logarithmic trendline (blue line) and the correlation coefficient of determination (R2) between
in vivo bioluminescence signals and total CFUs are shown. Data are expressed as mean CFUs 6 sem. *p,0.05 {p,0.01 S. aureus inoculated mice
versus uninfected mice (Student’s t-test).
doi:10.1371/journal.pone.0012580.g002
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euthanized mice on post-operative days 7 and 14 (Figure 5). To
evaluate biofilm formation, we used variable-pressure scanning
electron microscopy (VP-SEM), which allows for visualization of
biologic samples in their natural state, as there is no need to coat
them with a conductive film required for traditional SEM. Thus,
VP-SEM enabled the visualization of biofilms on the implants
without typical artifacts (dehydration, collapse, distortion, shrink-
age, condensation, and aggregation) associated with conventional
SEMs that require fixation and sputter coating. Mice inoculated
with S. aureus had prominent biofilm formation on the cut end of
the implants harvested on 7 and 14 post-operative days. In
contrast, uninfected mice, which did not have any bacterial
inoculation at the time of surgery, had no detectable biofilm
formation and the visualized metallic implant surface was virtually
identical to implants prior to surgery (Day 0). Thus, the bacteria
infected the joint tissue (Figure 4) and also formed a biofilm on the
implant, which is consistent with biofilm formation that occurs in
post-arthroplasty infections in patients [8–11].
A novel antibiotic-impregnated implant coating to treat
S. aureus post-operative joint infection
This mouse model was employed to determine the efficacy of a
bioresorbable polymer impregnated with rifampin and minocy-
cline in preventing the development of an infection in the joint.
This polymer was modified from a similar coating FDA-approved
to prevent infections of pacemakers and implantable cardioverter
Figure 3. Measurement of bacterial burden and neutrophil infiltration using in vivo bioluminescence and fluorescence imaging.
After surgical placement of an orthopaedic-grade stainless steel K-wire into the distal femur, 56102 CFUs/2 ml of S. aureus or 2 ml of saline alone
(uninfected) was inoculated into the knee joint in the area of the cut end of the implant (n = 6 mice per group). (A) Bacterial counts as measured by in
vivo S. aureus bioluminescence (mean maximum flux [p/s/cm2/sr] 6 sem) (logarithmic scale). (B) Representative in vivo bioluminescence on a color
scale overlaid on top of a grayscale image of mice. (C) Neutrophil infiltration (EGFP neutrophil fluorescence) as measured by in vivo fluorescence (total
flux [photons/sec]6 sem). (D) Representative neutrophil infiltration as measured by a color scale of fluorescence overlaid on top of a grayscale image
of mice. *p,0.05 {p,0.01 {p,0.001 S. aureus inoculated mice versus uninfected mice (Student’s t-test).
doi:10.1371/journal.pone.0012580.g003
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defibrillators (PivitTM AB and AigisRxTM CRM) [52]. Stainless
steel K-wires were coated by three coating formulations (Coatings
A, B and C), which contained increasing concentrations of the
antibiotics, and one vehicle control coating (no antibiotic)
(Figure 6A). In addition, Coatings A and B had the same thickness
and would elute the antibiotics at a similar rate whereas Coating C
was double the thickness and would elute slower.
These antibiotic-coated implants were surgically placed into the
distal femurs of LysEGFP mice and the knee joint space was
inoculated with 56102 CFUs of S. aureus. In vivo imaging was
performed on post-operative days 0, 1, 3, 5, 7 and 10 as in
Figure 3. Coatings B and C resulted in bioluminescence signals
that were highest at the time of inoculation and were reduced to
background levels by day 3 (Figure 6B). Coating A resulted in
bioluminescence signals that were less than the vehicle alone but
did increase between 0–3 days before decreasing to background
levels by day 7. As expected, the vehicle control coating, which
contained no antibiotics, did not inhibit bacterial growth and
resulted in bioluminescent signals that were up to 20-fold higher
than the initial inoculum and up to 50-fold higher than the two
most effective antibiotic-impregnated implant coatings (Coatings B
and C). Thus, the antibiotic-impregnated coatings substantially
reduced the bacterial burden and prevented infection in post-
operative joints as measured by in vivo bioluminescence imaging.
Since Coating A resulted in some bacterial growth, whereas no
growth was detected with Coatings B or C, it is likely that both the
drug concentration and elution rate contributed to the efficacy of
these coatings.
The antibiotic-eluting coated implants also substantially re-
duced clinical signs of inflammation. Mice with Coatings B and C
Figure 4. Histologic analysis. 56102 CFUs/2 ml of S. aureus or 2 ml of saline alone (uninfected) was inoculated into the knee joint in the area of the
cut end of the implant. At post-operative day 1, the implants were removed and the joint tissue was fixed in formalin, decalcified and embedded in
paraffin. Sagittal sections (4 mm) of the joint tissue were subsequently stained with hematoxylin and eosin (H&E) and Gram stain. Representative
photomicrographs of histologic sections are shown (1 of 3 mice per group, with similar results). Left large panels: low magnification (12.5x) of H&E
stained joint specimens with a line drawing of the location of the implant with the intramedullary canal seen within the femur. Upper right small
panels: higher magnification (100x) of H&E- and Gram-stained joint specimens of the boxed area in the left panel at the location of the cut end of the
implant within the joint. Lower right small panels: higher magnification (400x) of H&E- and Gram-stained section in the boxed areas in the upper right
panels.
doi:10.1371/journal.pone.0012580.g004
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ambulated with notably less guarding of the operative leg than
mice with vehicle-coated implants. To obtain a quantifiable
measurement of the infection-induced inflammatory response, in
vivo fluorescence of EGFP-neutrophils was measured in these
LysEGFP mice (Figure 6C). Coatings B and C, which were most
effective in reducing bacterial burden, had EGFP-neutrophil
fluorescent signals that were reduced to background levels (i.e. no
detectable inflammation) by post-operative day 5. These data
demonstrate that antibiotic-impregnated implant coatings mark-
edly reduced the infection-induced neutrophil recruitment and
inflammation in a concentration- and elution-dependent fashion.
To determine whether the antibiotic-impregnated implant
coatings had any impact on biofilm formation, the implants were
harvested from mice on post-operative day 7 and biofilm
formation was evaluated by VP-SEM (Figure 6D). All three
antibiotic-impregnated implant coatings (A, B and C) prevented
biofilm formation on the cut surface of the pin within the knee
joint. In contrast, the vehicle coated pin had readily detectable
biofilm formation.
Discussion
Infections after total joint arthroplasty represent a clinically
devastating complication [1,2]. These infections are exceeding
difficult to treat because the implanted materials provide avascular
surfaces to which bacteria adhere [8–11] and form biofilms, which
block the penetration of immune cells and antibiotics [53–59]. To
evaluate potential preventative or therapeutic strategies against
post-arthroplasty infection, we developed a mouse model of post-
arthroplasty S. aureus infection that provides real-time noninvasive
measurements of infection and inflammation. This mouse model,
which uses advanced in vivo bioluminescence and fluorescence
imaging, accurately detected a bacterial inoculum as low as
500 CFUs and noninvasively and longitudinally permitted mea-
surement of the bacterial burden and the ensuing neutrophil
inflammatory response in a live animal over the course of at least
10 post-operative days. The ability of only 500 CFUs of bacteria
to induce an infection in the post-operative joints is remarkable
given that an inoculum of 26106 CFUs was required in our
previous work to induce an infection in mouse skin [44–47]. This
is consistent with the notion that the immune-privileged site of the
joint combined with the foreign implanted material creates an
environment that is highly susceptible to bacterial infection [8–11].
The validity of this model was confirmed with (1) traditional CFU
counts, which demonstrated that in vivo bioluminescence highly
correlated with the numbers of CFUs adherent to the implants and
within the infected bone and joint tissue and (2) histologic analysis,
which demonstrated Gram-positive bacteria and neutrophil
infiltration in the surrounding joint tissue. Furthermore, high
resolution scanning electron microscopy techniques, VP-SEM,
enabled the visualization of biofilms that formed on the metallic
implants in their natural state without sputter-coating them with a
conductive film. Finally, this model was successfully used to
determine the efficacy of an antibiotic impregnated coating
containing minocycline and rifampin, to reduce the infection,
decrease inflammation and prevent biofilm formation on the
implants.
This mouse model of post-arthroplasty S. aureus infection has
unique elements that may complement or provide an alternative to
other previous animal models, which were performed in larger
animals, such as dogs, rabbits and rats [32–43]. First, this model
provides longitudinal, real-time quantification of the bacterial
burden and the neutrophil response in the infected joint. Unlike
the previous models, which required euthanasia to determine the
bacterial burden at subsequent time points (as tissue is required),
this model replaces euthanasia with noninvasive real-time in vivo
imaging. Second, previous models have presented few mechanisms
for accurately quantifying the infection-induced inflammation,
which is responsible for the clinical symptoms of swelling,
immobility and pain. In our model, a direct measurement of the
host neutrophilic inflammatory response in the infected post-
operative joints was obtained by combining the use of a mouse line
that possesses fluorescent neutrophils (LysEGFP mice) with
advanced in vivo fluorescence imaging techniques [47,48].
Additionally, as the wavelengths for bioluminescence (490 nm)
and fluorescence (515–575 nm) are distinct, the bacterial burden
Figure 5. Biofilm formation on the implant as visualized by variable-pressure scanning electron microscopy (VP-SEM). 56102 CFUs/
2 ml of S. aureus or 2 ml of saline alone (uninfected) was inoculated into the knee joint in the area of the cut end of the implant. At post-operative days
0 (before inoculation), 7 and 14, the implants were harvested and the cut ends of the implants that were in the joint space were analyzed for biofilm
formation by variable pressure-scanning electron microscopy (VP-SEM), which enables the direct visualization of the implants without the need for
sputter-coating. Representative VP-SEM images of the cut ends of the implants are shown (1 of 3 mice per group, with similar results). Top panels
represent a low power magnification (120x) and the bottom panels show a higher magnification (600x) of the area boxed in red. Biofilm formation is
readily seen from implants harvested from infected knee joints whereas only the metal surface is seen on implants from uninfected control mice.
doi:10.1371/journal.pone.0012580.g005
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and neutrophilic inflammatory response can be measured
sequentially within the infected post-operative joints longitudinally
in the same animals in real-time without the need for euthanasia.
Taken together, this mouse model of post-arthroplasty infection
provides longitudinal tracking of both bacterial burden and
inflammatory response while substantially reducing animal usage,
labor, material and experimental costs.
One limitation of the model described here is the use of the
SH1000 S. aureus bioluminescent strain which contained the lux
genes within a plasmid. Although the in vivo bioluminescent signals
correlated with the corresponding ex vivo bacterial CFUs, the
plasmid was only stable for the first 3 days of broth culture, such
that after this time point the in vivo bioluminescent signals obtained
using this strain may underestimate the actual bacterial burden. In
addition, other factors may additionally affect the rate of plasmid
loss. Future studies should be directed an improving this model, by
developing a S. aureus clinical isolate in which the lux genes are
inserted into the chromosome so that the bioluminescent signals
will not be lost over time. Alternatively, there are commercially
available S. aureus strains in which the lux plasmid is within the
chromosome such as Xen29 (Caliper Life Sciences) [60–62].
Lastly, we evaluated whether this mouse model could be used to
evaluate the efficacy of an antibiotic implant coating to reduce
infection. The antibiotic-impregnated bioresorbable tyrosine-
derived polymer coating, which slowly elutes minocycline and
rifampin, was clinically effective in reducing bacterial load,
preventing the infection, decreasing neutrophil infiltration/inflam-
mation and preventing biofilm formation on the implants. A
previous study in a rabbit intramedullary screw S. aureus
osteomyelitis model, found that minocycline and rifampin sprayed
Figure 6. A novel antibiotic-impregnated implant coating results in reduced S. aureus infection, decreased inflammation and
prevention of biofilm formation. Orthopaedic-grade stainless steel K-wires were machine cut and coated with increasing concentrations of a
tyrosine-based biodegradable antibiotic implant coating, which contained rifampin and minocycline or vehicle alone (coating without any antibiotic).
The rifampin/minocycline concentrations for each of the coatings were: Coating A: 32.5/36.1 mg/mm3; Coating B: 46.1/47.7 mg/mm3 and Coating C:
97.4/104.2 mg/mm3. Furthermore, Coatings A and B were the same thickness (,40–45 mm) and would elute at the same rate whereas Coating C
would elute slower because it had double the coating thickness (,80–90 mm). These coating implants were surgically placed into the distal femur
and 56102 CFUs/2 ml of S. aureus was inoculated into the knee joint in the area of the cut end of the implant. (A) Representative photograph of an
uncoated stainless steel implant and an antibiotic-impregnated coated implant. (B) Bacterial counts as measured by in vivo S. aureus bioluminescence
(mean maximum flux [p/s/cm2/sr] 6 sem) (logarithmic scale) (n = 5 mice per group). (C) Neutrophil infiltration as measured by in vivo fluorescence
(total flux [photons/sec] 6 sem) (n = 5 mice per group). (D) Representative VP-SEM images of the cut ends of the implants are shown (1 of 2 mice per
group, with similar results). Top panels represent a low power magnification (120x) and the bottom panels show a higher magnification (600x) of the
area boxed in red. *p,0.05 {p,0.01 {p,0.001 coatings A, B, or C vs. vehicle coating (Student’s t-test).
doi:10.1371/journal.pone.0012580.g006
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onto the implant without an elution polymer was only partially
effective in preventing colonization of the implant and infection of
the bone [39]. Although our study differed in the animal model
and method of bacterial inoculation, the presence of the antibiotic-
impregnated bioresorbable polymer was more effective, suggesting
that the elution of antibiotics may be an important factor when
developing antimicrobial implant coatings. These results suggest
that further study of this coating as a modality to prevent infections
associated with the use of orthopaedic implants is appropriate. It
should be mentioned that in addition to studying novel
antimicrobial implant coatings, this model could also be used to
evaluate other potential therapeutic strategies to treat biofilm-
associated infections, such as antibodies targeted against biofilm
factors [63].
There are some limitations of our mouse model of post-
arthroplasty infection. First, we recognize that this model
dramatically simplifies the steps involved in total knee arthroplasty:
we did not remove the cartilage surface from the femur or tibia, no
implant was placed on the tibial side and all implants were stainless
steel. There may have been interplay between the cartilage and
the bacteria in our model that would not occur in a human (as
cartilaginous surfaces are excised during the arthroplasty) and
other metals or materials used in a human arthroplasty may have
different susceptibilities to bacterial infection. Additionally, the
model and the antibiotic coating were used only to study infections
that were acquired during the surgical procedure and not against
late infections, such as those that occur through hematogenous
spread. Finally, it is clear that the elution properties of the
antibiotic from the alloys used in real implants would have to be
assessed before evaluating the efficacy of this strategy in human
patients.
Despite these weaknesses, we believe that the histologic,
bacterial cell counts and scanning electron microscopic data
confirms that our model depicts the in vivo behavior of bacteria on
and around metal implant in the setting of a post-surgical joint.
While all small animal models inherently simplify the surgical
procedure they aim to simulate, this model is unique in that it
provides real-time longitudinal tracking of infection and inflam-
mation in a post-surgical joint.
Taken together, this mouse model may serve as an alternative
noninvasive, cost-effective and accurate in vivo representative
model of a post-arthroplasty S. aureus infection. This model could
be potentially be used to provide important information about in
vivo clinical efficacy of preclinical preventative or therapeutic
modalities against post-arthroplasty infections before more exten-
sive studies in larger animals and in human subjects.
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